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THE topical glucocorticoids (GCs) represent the treat-
ment  of  choice  for  many  types  of  inflammatory
dermatoses. Despite the extensive use of this class of
drugs  as  first  line  therapy  the  mechanism  of  their
action is uncertain. It is clear that the multiplicity of
actions  of  the  topical  GCs  is  an  important  facet  of
their scope in the treatment of dermal disorders. The
aim  of  this  update  is  to  review  past  and  current
theories  regarding  how  these  agents  might  work.
Current understanding of the molecular mechanisms
of GC action has advanced significantly over the past
decade with the realisation that multiple systems are
responsible for transduction of GC effects at a molec-
ular level. The two primary modes of action are via
interaction directly with DNA or indirectly through
modulation of specific transcription factors: the end-
point  in  both  cases  being  modulation  of  specific
protein synthesis. Both of these mechanisms will be
discussed. In particular this review will concentrate
on the possibility that a GC-inducible protein, termed
lipocortin 1, may have a significant role to play in the
anti-inflammatory  actions  of  these  drugs.  Addition-
ally it has become apparent that several inflammatory
enzymes induced in inflammation are sites of inhibi-
tory action of  the GCs, and the possibility that this
occurs in the skin will be discussed paying particular
attention  to  the  inducible  phospholipase  A2,  nitric
oxide synthase and cyclooxygenase systems.
Key  words:  hipocortin    1,  annexin  1,  dexamethasone,
inflammation, nitric oxide synthase, cyclooxygenase, phos-
pholipase A2
Introduction
Topical glucocorticoid (GC) treatment of inflamma-
tory disease was first recognized as a viable mode of
therapy  by  the  ophthalmologists. These  specialists
were  quick  to  realize  the  potential  of  the  GCs  in
inflammatory  ocular  conditions  following  Hench’s
description  in  1949  of  his,  Noble  Prize  winning,
studies demonstrating the anti-inflammatory effects of
steroid treatment in rheumatoid arthritis.1The derma-
tologists  followed  suit  confirming  the  efficacy  of
these  agents  in  skin  disease. These  rather  humble
beginnings initiated the ensuing revolutionary chan-
ges in the treatment of inflammatory skin conditions
commencing with the first, albeit unsuccessful, trials
with topical cortisone in 19502 and 1951.3 However
soon after, in 1952, Sulzberger and Witten published
the first well-controlled trial demonstrating the clear-
cut benefits of topical hydrocortisone in patients with
inflammatory dermatological conditions.4 The 1960s
were the golden era for the GCs with the introduction
of the first synthetic congeners (e.g. prednisolone)
into the clinic, followed soon after by the fluorinated
derivatives (such as dexamethasone) possessing much
increased potency. The unmatched efficacy of these
agents when treating skin disease has in part resulted
in the neglect  afforded to  understanding the  exact
mechanisms  of  action  of  the  topical  GCs.  The
existence of a facile assay system for estimation of
potency, termed the vasoconstrictor assay (described
later), aided and abetted this situation. More recently,
however, understanding of the mechanisms of steroid
action, in systems other than the skin, has advanced
significantly and several groups are now pursuing this
newly  gained knowledge  with  respect  to  the  skin.
This article reviews the past and present theories of
the mechanism of action of the glucocorticoids with
specific reference to their use in the treatment of skin
disease.
Mechanism of Action
The GCs have a multiplicity of actions; anti-inflamma-
tory, immunomodulatory, vasoconstrictor, gluconeo-
genic, anti-mitotic to name a few (see Table 1). It is
believed that several of these actions contribute to the
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skin  disease.  Indeed  it  is  often  this  multi-pronged
attack  that  endows  the  GCs  with  the  considerably
greater  therapeutic  potency  above  other  modes  of
treatment.  On  the  downside  however  it  is  this
plethora of disparate effects that may preclude their
use, since to date it has not been possible to separate
the required actions of the GCs from those that cause
significant unwanted side-effects. Due to the diversity
of conditions that the GCs may be used to treat it is
important to appreciate that any particular action of a
GC may be beneficial in the treatment of one disease
yet  responsible  for  a  confounding  side  effect  in
another. For instance, the anti-mitotic nature of GCs is
the  property  upon  which  their  use  in  psoriasis  is
based,5 yet in the treatment of other inflammatory
dermatoses results in skin atrophy and may often be
the reason for cessation of topical GC treatment.
Topical  GCs  are  prescribed  for  the  treatment  of
many  inflammatory  conditions and today represent
the  drug  type of choice for  the treatment of  most
dermal inflammatory disease (Table 2). This is not to
say that  the topical GCs are a panacea  for  all skin
disease,  but  perhaps  may  be  regarded as  the  most
effective single class of drugs providing such broad
spectrum therapeutic benefit. The anti-inflammatory
action of the topical GCs has variously been attributed
to several different mechanisms, and it is now clear
that it is a combination of the different properties of
the GCs that act in concert to provide the therapeutic
advantages of this class of drugs in the treatment of
inflammatory skin disease. Additionally both the anti-
mitotic  and  vasoconstrictor  nature  of  the  GCs  are
properties which,  most likely, contribute to resolu-
tion of certain inflammatory  skin disease. The anti-
mitotic  effect  is  believed  to  confer  the  beneficial
effects of topical GCs in the treatment of psoriasis, a
disease characterized by a high cell turnover rate (for
review  see  Van  De  Kerkhof  and  Van  Erp6).  The
vascular  effect  i.e.  vasoconstriction,  also  termed
‘blanching’  when  applied  to  the  skin  surface,  has
been suggested to contribute to the anti-inflammatory
effects of these drugs by virtue of the decreased blood
flow to the inflamed site, however the mechanism for
this effect is still unclear (for review see Walter and
Williams7). Additionally it is this blanching response
which forms the basis of the standard assay for the
assessment  of  the  potency  of  topical  GCs.8,9 The
immunosuppressive nature of these agents also con-
fer benefit in treatment of dermal diseases and indeed
experimentally it is clear that steroids block delayed
hypersensitivity responses in the skin.
Molecular mechanism of action
T opical GCs interact with GC receptor
The specific biological actions of the topical steroids
are  brought  about  by  interaction  with  the  GC
receptor.  In  the  1960s  and  1970s  several  studies
provided  circumstantial  evidence  supporting  the
concept of steroid binding sites in skin by demonstra-
tion, for example, of [14C]-cortisol retention in the
stratum  corneum10 and  identification  of  soluble
proteins with high affinity for certain GCs in rat skin
homogenates.11 It  was  in  1971  that  definitive  evi-
dence for the existence of these receptors in mouse
skin  was  obtained,12 followed  by  confirmation  of
these receptors in humans, firstly in cultured human
keratinocytes  and  langerhan  cells  and  then  human
epidermis.13–15
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Table  1.  Mechanisms  of  anti-inflammatory  action  of  the
topical glucocorticoids
Action Effect
Inhibition of
phospholipase A2 activity
Decreased production of
lipid mediators
(prostaglandins,
leukotrienes, platelet-
activating factor)
Inhibition of
cyclooygenase induction
Decreased prostaglandin
production
Inhibition of nitric oxide
synthase induction
Decreased nitric oxide
production
Inhibition of cytokine
production
Suppression of cell-
mediated inflammation
Inhibition of mast cell
activity and reduction of
mast cell number
Decreased levels of mast
cell inflammatory
mediators (histamine,
5-HT)
Vasoconstriction Decreased local blood
flow
Table 2. Inflammatory dermal diseases treated with topical
glucocorticoids
Level of treatment Disease
Treatment of choice Eczema
Contact dermatitis
Atopic dermatitis
Lichen planus
Lichen simplex chronicus
Chronic dermatitis
Neurodermatitis
Insect and arthropod bites
Burns and sunburns
Keloids
Useful alternative or
adjunctive therapy
Psoriasis
Seborrhoeic dermatitis
Chronic lupus
erythematosus
Alopecia areata
Acne
Isolated examples of
successful treatment
Bullous pemphigoid
Cutaneous mastocytosis
VitiligoThe subcellular localization of the GC receptor is a
matter of debate. Early immunocytochemical studies
concluded  that  the  GR  in  the  unoccupied  state
remains primarily in the cytoplasm and it is only upon
occupation  with  a  GC,  to  form  a  GC-receptor
complex  (GC-R),  that  it  translocates  to  the
nucleus.16,17 This pattern of activity is quite different
from all of the other members of the steroid receptor
family  i.e.  oestrogen,  progesterone  and  androgen
receptors, however more recently it has been demon-
strated that the mineralocorticoid receptor functions
in a similar manner.18 In contrast some studies suggest
that the receptor is solely nuclear,19,20 and the authors
in these  cases  attribute  this  apparent  difference  in
localization  to  immunocytochemical  procedure.
Recent studies agree with cytoplasmic alocalization of
the receptor but in association with the microtubule
network (for review see Akner et al.21). This associa-
tion with cytoskeletal filaments may explain how the
GC on binding to the receptor is transported to the
nucleus. In contrast some studies show no association
of  the  cytosolic  receptor  with  microtubular  fila-
ments.22 The prevailing belief at the present time is
however that the receptor is cytoplasmic and trans-
locates to the nucleus once bound to GC.
Specific GC functionality is conferred by binding to
the receptor and this has been demonstrated for many
of  those  effects  which  are  anti-inflammatory.  For
example  both  oestradiol  and  testosterone,  full  GC
receptor  antagonists,  were  shown  to  block  the
blanching  activity  of  clobetasol-propionate  in  the
human forearm.23This was supported by later studies
with  the  GC  receptor  antagonist,  RU38486,  where
prior systemic treatment of human volunteers with the
antagonist completely blocked the blanching response
to topically applied clobetasol-propionate.24
GC-R complex activity
(i) Interactions with DNA. Classically the mechanism
of action of the GCs was thought to be brought about
by  changes  in  gene  expression.  It  is  now  clear,
however, that there are two modes of action of the
activated GC receptor; those via interactions directly
with DNA and those through protein–protein inter-
actions with transcription factors. The end-point in
each  case  is  the  same  i.e.  the  alteration  of  the
synthesis of key proteins.
Once  the  GC  crosses  the  cell  membrane  it  is
thought that it binds with cytoplasmic receptor (R) to
form a GC-R complex. The unliganded receptor is a
heterotetrameric  complex  comprised  of  heat-shock
proteins  (hsp),  hsp70  and  hsp90,  and  chaperone
immunophilins (for reviews see Pralt25 and Smith and
Toft26). The sequelae following GC-R complex bind-
ing  with  DNA  have  been  characterized  and  it  is
thought that interaction with genomic DNA accounts
for most GC-induced effects (for a recent review on
GC-receptor binding mechanisms see Brann et al.27).
Briefly GC-receptor binding causes a conformational
change of the receptor with consequent shedding of
the DNA-binding domain capping protein, hsp90.28,29
Exposure of the DNA-binding site allows binding of
the GC-R complex to the GC response element (GRE).
This interaction stimulates alterations in transcription,
either positively or negatively, and thereby translation
of proteins. One particular anti-inflammatory protein
that is induced in this way is lipocortin 1 (LC1), also
known  as  annexin  1,  a  member  of  the  annexin
family.30This protein has attracted considerable inter-
est as an important mediator of the anti-inflammatory
action of the GCs and this review will highlight the
activity of this protein in particular.
(ii)  Protein–protein  interactions.  Whilst  a  con-
siderable component  of  GC-R  complex  activity  has
been  attributed  to  interaction  with  GREs,  gene
repression  may  also  be  modulated  indirectly  by
protein–protein  interactions  between  the  activated
GR and other transcription factors thereby altering
protein synthesis without binding to GREs. Of partic-
ular  interest is the inhibitory effect of GCs on two
essential regulatory  transcription  factors for several
genes involved in the inflammatory process; AP-1 and
NFk B.  These  factors  regulate  the  expression  of
inflammatory cytokines and adhesion molecules and
indeed inhibition of the activity of these transcription
factors  has  profound  effects  on  inflammatory  and
immune responses.31,32
Whilst it seems clear that the GC-R complex binds
directly with AP-1, thereby blocking AP-1-dependent
gene  expression,33 the  mode  of  interference  with
NFk B is less clear. NFk B exists constitutively in the
cytosol as a heterodimer (p50 and p65 subunits), and
is maintained in an inactive form by association with
Ik B.34 Exposure  to  inflammatory  stimuli  results  in
rapid  degradation  of  Ik B  allowing  free  NFk B  to
translocate  to  the  nucleus  where  it  binds  with
promoter  elements  on certain  inflammatory  genes.
Originally it was thought that the GC-R complex binds
directly with NFk B, however in 1995 it was shown, in
a cultured monocytic T -cell hybridoma cell line, that
the activated receptor may decrease free NFk B levels
by upregulating Ik B transcription.35,36 Increased Ik B,
in turn, would sequester NFk B thereby depressing the
levels  of  free  NFk B  available  for  binding  to  target
genes. This theory however has not been uniformly
accepted  with  studies,  in  primary  endothelial  cell
cultures,  showing  that  GC-induced  repression  of
NFk B is not related to elevations of Ik B but rather to
direct  binding  of  the  activated  GC  receptor  to
NFk B.37 The complication of the latter mechanism is
that  once  GC-R  complexes  have  been  formed  the
complex is rapidly translocated to the nucleus whilst
the  protein–protein interaction,  proposed between
NFk B  and  the  GC-R  complex  presumably  must  be
cytoplasmic. Studies in the adenocarcinoma A549 cell
line suggest that in the absence of an inflammatory
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however  in the  presence  of  an  inflammatory  cyto-
kine, such as tumour  necrosis factor alpha (TNFa ),
GC-R complexes remain within the cytoplasm where
they are then available for interaction with transcrip-
tion factors.38 How this retention in the cytoplasm is
brought about is unclear but the authors indicate that
such a mechanism would allow cytoplasmic protein–
protein interaction.
Without doubt the modulation of NFk B by the GCs
represents an important potential mechanism of anti-
inflammatory action. Interpretation of studies demon-
strating GC-induced suppression of NFk B levels are
complicated by the fact that, in the large part, the
concentrations of GC used for these studies have been
high  (0.1–1m M). Whether  these  concentrations  in
vivo relate to those achieved during treatment39 is
uncertain. Additionally other  studies  show  that  the
non-steroidal anti-inflammatory  drugs (NSAIDs) also
have  the  capacity  to  effectively  suppress  NFk B
levels.40 Since there is an enormous disparity between
the effects of the GCs and the effects of the NSAIDs this
suggests that mechanisms other than protein–protein
interactions are also important in mediating the effects
of the GCs at a molecular level.
Inhibition of pro-inflammatory enzyme activity
The  inflammatory  response  in  the  skin  involves
several soluble mediators. The prostanoids and nitric
oxide  (NO)  represent  two  important  groups  of
inflammatory mediator41 that have attracted consider-
able attention as sites of anti-inflammatory action of
the GCs. The pathways involved in the production of
these two types of mediator are known to be prone to
inhibition  by  the  GCs  and  it  is  now  clear  that
decreased  production  of  either  of  these  class  of
mediators has a significant impact on many aspects of
an  inflammatory  response.41 With  respect  to  the
prostanoids  the  GCs  suppress  the  induction  of
phospholipase A2 (PLA2) and cyclooxygenase-2 (COX-
2),  both  enzymes  involved  in  the  phospholipid-
arachidonate cascade (see Fig. 1). Importantly inhibi-
tion of PLA2 activity will not only suppress prostanoid
levels  but  will  also  attenuate  production  of  the
leukotrienes  and  platelet-activating  factor;  other
important  mediators of inflammation.  Similarly it is
the synthesis of NO that is targeted by the GCs i.e.
inhibition  of  NO  synthase  induction,  an  enzyme
imperative for NO synthesis during inflammation.41
Overproduction  of  either  prostanoids  or  NO  is
brought about by the induction of certain inducible
enzymes that  belong to the class of early response
genes. Interestingly it seems that at a molecular level
it is the early response genes which are particularly
sensitive  to  GC  action. These  mechanisms  of  GC
action will be discussed below with particular refer-
ence to their action in skin.
Phospholipase A2 (PLA2)
The first significant studies attempting to determine
the  site  of  antiinflammatory  action  of  the  GCs
pinpointed the enzyme PLA2 as  the most  probable
site. PLA2 activity results in conversion of membrane
phospholipids  into  arachidonic  acid  and  lysoPAF .
Arachidonic acid is the substrate for both COX-1 and
COX-2  enzymes,  the  activities  of  which  produce
various prostanoids some of which possess inflamma-
tory  activity.  It  was  in  1974  that  the  first  report
demonstrating that hydrocortisone reduced the out-
put of prostaglandin (PG) E-like substances, in exer-
cised dogs,  was  published.42 Soon  after  this  initial
observation  it  became  clear  that  this  decreased
prostanoid  production  was  a  consequence  of  sup-
pressed arachidonic acid release, implicating PLA2 as
the site of GC action rather than direct inhibition of
COX activity.43,44 This appears to be true for topical
GCs  in  the  skin  since  abnormally  high  levels  of
arachidonic acid, in psoriatic plaques, are reduced by
topical GC treatment.45,46 Furthermore PLA2 activity
in psoriatic  plaque  samples  is suppressed  in those
patients previously treated with topical GC.47 It has
even  been  proposed  that  measurement  of  PLA2
activity in psoriatics could efficiently form the basis of
a model for the assessment of topical GC potency. In
light  of  this  evidence  it  was  suggested  that  a
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FIG. 1. The lipid mediator cascade.reduction, by the GCs, of the elevated levels of PLA2
was  primarily  responsible  for  the  benefits  of  this
treatment in disease such as psoriasis and eczema.48
Whilst  it  is  clear  that  GC  treatment  attenuates  the
abnormally  high  levels of  arachidonate products in
psoriatic  skin  it  remains  unclear  as  to  what  event
comes  first;  decreases  in  the  levels  of  these  sub-
stances and consequently plaque resolution or plaque
clearance  followed  by  normalization  of  prostanoid
levels.
The mechanism of GC-induced inhibition of PLA2
was  first  unravelled  by  the  pharmacologists  using
classical bioassay techniques, in this case the guinea-
pig perfused isolated lung preparation. The guinea-pig
lung  can  be  stimulated  to  release  prostanoids  by
perfusion with either the substrate, arachidonic acid,
or by other substances such as histamine or bradyki-
nin.  Using  these  techniques  a  series  of  elegant
experiments demonstrated that the GC, dexametha-
sone,  inhibited  prostanoid  release  induced  by  the
prostanoid-releasing substances but not by addition of
the substrate, and most importantly that this process
required de  novo protein synthesis.49,50 Soon after
these seminal experiments the protein responsible for
this  effect  was  identified  by  several  independent
groups  simultaneously.  In  1984  these  groups  came
together and proposed a common nomenclature for
the  protein,  lipocortin  1  (LC1).51 Since  this  time
several different groups have demonstrated the anti-
inflammatory potential of this protein in pathological
situations. Additionally the role of this protein as a
physiological  regulator  was  proposed  in  1992  by
Vishwanath et al.52This group showed that the levels
of  both  LC1  mRNA  and  protein  were  significantly
decreased in adrenalectomized rats. From these find-
ings  this  group  proposed  that  LC1  may  be  an
important defence mechanism and decreases in the
levels  of  this  protein may  predispose  to  enhanced
inflammatory or immunological processes. In much
the same way as the GCs the mechanism of action of
LC1 was believed initially to be solely via inhibition of
PLA2,  however  recent  advances  suggest  that  this
inducible protein possesses multiple sites of action in
inflammation which are both cellular and non-cellular
(for review see Perretti53).
LC1  was  thought  to  inhibit  conversion  of  mem-
brane phospholipids to arachidonic acid by a direct
action on PLA2 and indeed there are recent studies
with porcine splenic  PLA2 which  concur  with this
proposition.54 More recently however this theory has
come  under  considerable  scrutiny.  In  vitro studies
using  Escherichia  coli cells  or  porcine  pancreatic
PLA2 show clearly that LC1 inhibits PLA2 activity,55
however  this  effect  was  not  due  to  direct  binding
with  the  enzyme  but  rather  by  binding  to  the
phospholipid substrate. This results in depletion of
substrate availability and hence apparent decreased
PLA2 activity. Studies measuring PLA2 activity in full
thickness human skin homogenates agree with these
findings showing that LC1-induced inhibition of PLA2
activity is a function of substrate concentration and
moreover, that LC1 competes with PLA2 for phospho-
lipid substrate.56 In  contrast  recent  studies  suggest
that phosphorylation of PLA2 precedes and procures
enzyme activation and further that this phosphoryla-
tion is sensitive to dexamethasone in a LC1-depend-
ent manner.57 Finally the GCs may alter PLA2 expres-
sion itself by an effect at the level of the gene which
possesses a GRE (e.g. Schalkwijk et al.58). Whatever
the mechanism of the induced decrease in conversion
of membrane phospholipids into arachidonic acid the
end-point remains the same i.e. resultant decrease in
arachidonate products. Up till now there have been
no  direct  studies  either  using  epidermal  cells  in
culture or in vivo to demonstrate directly that LC1, or
any other lipocortins, alter the levels of arachidonate
products in the skin and are likewise associated with
a resolution of the disease.
(i) Lipocortin 1 in skin
In 1989 Fava and co-workers were the first to identify
basally  expressed  LC1  in  rat,  porcine  and  human
skin.59 The  exact  cellular  location  of  this  protein
remains somewhat unclear with contradictory results
from several different groups. Using antibodies gen-
erated  by  their  group  Fava  showed,  immunohis-
tochemically,  that  LC1  could  be  found  in  discrete
areas. The protein was situated predominantly in basal
keratinocytes of the basement membrane. Staining for
LC1  was  also  present  in  the  epithelium  of  sweat
glands in pig and human skin. Additionally, in human
skin, there was an intense staining in the epithelial
cells  of  hair  follicles.  However  other  studies  have
identified a different cellular localization for LC1 in
the  skin.  For  instance  Kitajima’s  study  in  1991
localized basal LC1 expression to the suprabasal layer
of human skin, predominantly keratinocyte.60 It has
been suggested that these differences between stud-
ies  may  reflect  binding patterns  of  antibodies  gen-
erated against different epitopes of the LC1 molecule
and suggest that LC1 may adopt different intercellular
conformational states.
The  intracellular  location  of  LC1  is  also  con-
troversial.  Indeed it is now  believed that  there are
multiple  pools  of  LC1  with  only  certain  compart-
ments conferring the biological activity of this pro-
tein. Figure 2 shows a schematic of the different pools
of LC1 which have been identified. In the skin LC1
was found within the cytoplasm of epidermal cells in
vitro,60 an observation supported more recently by
studies in human skin biopsies, where LC1 was found
in the cytoplasm  of  cells  of  the upper and middle
epidermal layers.61 Of interest is the demonstration
that  in  disease  the  intracellular  localization  of  LC1
appears to change. In lesional psoriatic skin LC1 is
found only in the cell membrane with no staining in
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tion  of  the  protein.60,62 It  is  possible  that  the
movement of LC1 to the cell membrane is an active
protective  response  of  the  cell  in  disease  and,  as
suggested  by  the  authors,  may  occur  to  allow  the
binding of LC1 to phospholipids thereby decreasing
inflammatory  prostanoid  production.  However  the
movement of LC1 was also associated with increases
in the EGF receptor/tyrosine kinase, for which LC1 is
a  substrate,  and therefore  it  could  be  that  the  net
availability of LC1 is in fact reduced. All of the studies
mentioned so far have concentrated on the expres-
sion of basal LC1 in skin and its possible alteration in
skin disease. We however addressed the concept that
LC1  may  be  a  mediator  of  the  anti-inflammatory
effects of topical GC therapy.
(ii) LCI expression in skin is GC-sensitive. Studies
in  rat  have  clearly  demonstrated  that  topical  GC
treatment  of  the  skin  results  in  alterations  in  LC1
expression. Although measurement of the total LC1
content in skin homogenates showed no differences
between GC-treated and vehicle-treated skin, exam-
ination of the pericellular compartment of LC1 using
Western  blotting,  demonstrated  that  a  pericellular
pool of LC1 increases following topical GC treatment
(betamethasone-17-valerate  0.018mg/cm2 in  ace-
tone).63 Figure 2 shows schematic representation of
the pools of LC1 thought to exist in the cell. Recently
it has been suggested that the pericellular compart-
ment of LC1 provides the biological activity of this
protein. This proposal is supported by the fact that
induced LC1 expression, in vivo, may be neutralized
with  antibody  generated  against  this  protein.64,65
Indeed  pericellular  LC1  expression,  induced  in  rat
skin, increased to a maximum at approximately 3h
following topical treatment returning to basal levels
by  18h.  This  alteration  of  LC1  levels  was  also
temporally associated with anti-inflammatory activity
with  approximately  50%   inhibition of  oedema pro-
duced in response to a range of putative mediators of
inflammation.66 This  change  in  LC1  levels  was  a
specific  effect  of  the  GC  since  pretreatment  of
animals  with  the  selective  GC  receptor  antagonist,
RU38486, prevented these differences. The situation
in man is somewhat similar with an increase in LC1
expression  in  the  pericellular  compartment  over  a
similar time  course  (A. Ahluwalia  and R. J. Flower,
unpublished observations). Unlike these studies oth-
ers  have  found  no  increase  in  total  LC1  levels
following GC treatment of epidermal cells in vitro.67
This group showed that 16h following treatment of
cells  with  dexamethasone  there  was  a  significant
decrease in the total expression of LC1 in both the
cytosol  and  membrane  of  these  cells.67 However
these studies looked neither at shorter time points
following  treatment  nor  at  the  different  compart-
ments independently. If there had been an increase in
the expression of the protein pericellularly it may be
that this increase is achieved via the translocation of
LC1  from  either  the  intracellular  or  membranous
compartments without necessarily a change in total
LC1 content. This of course in turn would result in a
decrease in the LC1 levels in the latter compartments
which may explain the decreases in the protein seen
in the epidermal cells at the 16h timepoint. In A549
adenocarcinoma  cells  pericellular  LC1  expression
increased following dexamethasone treatment, reach-
ing a maximum after 2h.64 Recently this same group
have shown, by measuring incorporation of labelled
amino acid, that following GC treatment new protein
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FIG. 2. Cellular distribution of distinct compartments of lipocortin 1.synthesized by the cells was specifically directed to
the cell surface in contrast  with incorporation into
the  intracellular  compartment  in  the  absence  of
GC.68
In a separate series of investigations the involve-
ment  of  induced  LC1  in  procuring  the  effects  of
topical GC treatment in vivo have also been investi-
gated. Our group have shown that the same topical
GC regimen, as used in the above studies, resulted in
an inhibition of the oedema produced in response to
neurogenic stimulation; electrical stimulation of the
saphenous  nerve.  Furthermore  prior  LC1  immuno-
neutralization  of  rats,  by  systemic  treatment  with
antibody, partially inhibited the anti-oedema effects of
the  GC.69 In  another  model  of  skin  inflammation
using intradermal administration of various putative
mediators of inflammation, including platelet activat-
ing  factor  and  5-hydroxytryptamine,  the  inhibitory
effects of topical GC treatment was also reversed by
prior  immunoneutralization  with  LC1  antibody.66
These results together suggest that at least some of
the anti-inflammatory effects of the topical GCs in the
skin are brought about by the GC-inducible protein
LC1.
The beneficial  effects  of  the topical  GCs  in skin
disease are not however restricted solely to their anti-
inflammatory  properties. The  anti-mitotic  nature  of
these agents has been proposed to provide benefits in
psoriasis where the cell turnover rate of the skin is
considerably elevated above basal. Although there are
now topical formulations believed to have little effect
on cell turnover but retaining significant anti-inflam-
matory  activity  such  as  fluticasone.70 Studies  in
normal  skin  showed  that  topical  GC  treatment
resulted in a significant decrease in epidermal mitoses
in  comparison  with  that  in  vehicle  controls71 and
similar findings have been shown in psoriatic skin.72
Dexamethasone  has  profound  anti-proliferative
effects  on  the A549  cell  line  and  moreover  these
effects  are  associated  with  increases  in  LC1  and
blocked  by  pretreatment  of  the  cells  with  specific
neutralizing  antiserum  to  LC1.64 Studies  using  the
hairless  mouse  comparing  the  mitotic  index  and
3H-thymidine uptake in normal and GC-treated skin
suggest that the effect of the GC may be a non-specific
cell cycle effect or at the G1 interphase period.73 On
a more speculative note it  would be interesting to
determine  whether  the  anti-mitotic  effects  of  the
topical GCs are brought about by LC1. This may then
identify novel therapeutic opportunities for the treat-
ment  of  psoriasis and importantly  possibly identify
the  mechanism  of  skin thinning,  a  significant  side-
effect of topical GC treatment.
Cyclooxygenase (COX)
Over the past decade there has been a growing body
of evidence demonstrating that the GCs alter prosta-
noid synthesis by modulating the pathway at several
levels. Studies in various cells types in vitro, including
human dermal fibroblasts, have shown that the GC
dexamethasone inhibits cytokine-stimulated COX syn-
thesis.74Whilst early studies demonstrated clearly that
GCs had no effect on normal eicosanoid synthesis in
either  mice  or  man,  other  studies  show  that  in
situations where expression of COX has been upregu-
lated, such as following treatment with pro-inflamma-
tory  substances  including  cytokines  and
lipopolysaccharide,  prostanoid  synthesis  becomes
sensitive to GC treatment.75 These differences whilst
initially  puzzling  have  been  explained  with  the
discovery that there are two isoforms of this enzyme;
the constitutively expressed enzyme found in most
cell types called COX-1, and an inducible form found
in inflammatory cell types called COX-2.76The COX-1
and COX-2 genes have now been cloned and show
approximately  60%   homology.77–79 It  appears  that
whilst  the  induction  of  COX-2  is  sensitive  to  GC
treatment  the  expression  of  COX-1  is  not  (see
Herschmann79 for review). Furthermore GC-induced
decreases in COX-2 expression is due to a decrease in
the stability of  the mRNA rather than  an  effect  on
transcription per se.80,81
In  vitro it  is  clear  that  it  is  the  up-regulated
prostanoid synthesis stimulated by COX-2 that is GC-
sensitive.  In  vivo animal  studies,  however  have
uncovered the fact that endogenous GCs are impor-
tant regulators of basal prostanoid production since
the lethal response to LPS in animals is more severe in
adrenalectomized  animals.82,83 Additionally  adrena-
lectomy  of  mice  results  in  substantial  increases  in
COX expression and prostanoid production in perito-
neal  macrophages,  that  is  associated  with  an
increased lethality.84 Later  studies showed that  this
enhanced  COX  expression  was  of  the  COX-2  iso-
form85 suggesting  that  constitutive  expression  of
COX-2 in murine peritoneal macrophages is tonically
regulated by endogenous glucocorticoid.
Not all studies are consistent with the hypothesis
that  GCs  downregulate  COX  activity  and  in  some
cases  it  seems  that  GC  treatment  has  no effect  or
conversely  elevates  prostanoid  production  (for
review  see  Duval  and  Freyss-Beguin86).  In  murine
bone-marrow-derived mast cells dexamethsone selec-
tively  induces  COX-1  expression  with  consequent
elevation of PG formation.87 Whilst this potentiatory
effect  may  at  first  appear  contradictory  on  closer
inspection this elevation may be advantageous to the
organism since in certain situations PGE2, at least, is
anti-inflammatory.  In  rat  and  murine  skin  in  vivo,
PGE2 inhibits oedema formation induced by inflam-
matory stimuli including platelet-activating factor and
zymosan  activated  serum.88 The  authors  demon-
strated  that  this  inhibitory  effect  of  the  PGs  is
mediated by the prostanoid EP3 receptor. Support for
these  findings  in  man  show  that  misoprostol,  the
selective  EP3 receptor  agonist,  inhibits  antigen-
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Inhibition  of  elevated  prostanoid  production  and
enhancement  of,  or  even  no  effect  upon,  basal
prostanoid  production  would  provide  an  ideal
approach for anti-inflammatory treatment with block-
ade  of  the  damaging  over-production  of  PGs  and
preservation  of  basal,  potentially  anti-inflammatory,
PG production.
Nitric oxide synthase (NOS)
Nitric oxide (NO) plays an important role in several
systems  modelling  physiological  and  pathological
processes in the skin including; vasodilatation, inflam-
mation, immunomodulation and oxidative damage to
cells and tissues (for review see Lyons90). As such NO
represents another important possible site of action
of the GCs. NO is synthesized by a family of enzymes:
the nitric oxide synthases of which there are three
isoforms–the constitutive endothelial eNOS and neu-
ronal nNOS (also collectively known as cNOS) and the
inducible iNOS.  GCs  inhibit the  induction of iNOS
whilst leaving cNOS activity untouched. Studies in the
early 1990s demonstrated that the GCs inhibited NO
production only in situations where NO production
was elevated by inflammatory substances such as LPS
or  cytokines,  much  in  the  same  way  as  the  COX
system.  The  similarity  between  the  two  enzyme
families extends further in that cNOS like COX-1, and
in contrast to iNOS or COX-2, is resistant to modula-
tion by GC treatment.90
NOS  is  expressed  in  skin  and  this  has  been
demonstrated in animal91 and human skin.92 Indeed
intradermal application of an NO synthase inhibitor
causes decreases in local skin blood flow in animals93
and man.94 Thus  it  appears that  NO  is involved in
basal  dermal  blood  flow.  Recent  evidence  shows
significant  increases  in  NO  production  in  several
dermal  pathologies and it has been postulated that
this  elevated  NO  contributes  to  the  aetiology  of
certain skin diseases. Studies using the NOS inhibitors
suggest  a  role  for  NO  in  erythema  and  oedema
formation  in  psoriasis  and  atopic  dermatitis.94,95
Additionally  iNOS  is  present  in  lesional  psoriatic
skin96,97 and specifically in involved sites in patients
with atopic dermatitis and allergic contact dermati-
tis.96 It is clear that enhanced NO production, due to
iNOS activity, may have a significant role to play in
inflammatory skin conditions.
Thus it may be possible that resolution of inflamma-
tory skin conditions with the GCs may be due, at least
in part, to the inhibition of iNOS induction in the skin.
There have been no studies, as of yet, which have
clearly demonstrated that following topical GC treat-
ment there is a consequent reduction of iNOS activity
in sites subjected to an inflammatory stimulus such as
LPS  or  carrageenin  or  indeed  in  human  skin
biopsies.
Modulation of mast cell activity
An alternative mechanism for the anti-inflammatory
action of GCs has been proposed to be the modula-
tion of mast cell numbers and activity. Degranulation
of mast cells with consequent  release of histamine
plays  a  major  role  in hypersensitivity  responses  as
well as contributing to other types of inflammatory
skin diseased states. Mast cells possess high affinity
IgE receptors and in atopic individuals exposure to
antigen  results  in  degranulation  since  the  antigen
binds to the IgE attached to the receptor. The mast
cell contains several pro-inflammatory mediators and
degranulation  will  consequently  release  these  pro-
inflammatory substances, such as histamine and PGs,
into the local environment.98 Therefore inhibition of
this mast cell component should have significant anti-
inflammatory effects. Topical GC treatment causes a
decrease in mast cell numbers in the skin99 and this
decrease in numbers is responsible for the decrease in
histamine content of the treated skin. Despite initial
studies with human skin in vitro showing that GC
treatment, for only 2h, attenuates histamine release in
response to allergen challenge100 early studies in the
airways, in vivo, suggested that the GCs had no effect
on histamine release in an allergic reaction. However
it has become clear that duration of treatment with
GC  is  an  important  determinant  of  the  efficacy of
these  agents  in  the  skin.100 Indeed  a  1–2  week
treatment with topical GC causes complete block of
the allergen-induced late response and attenuates the
immediate wheal and flare response in the skin of the
human forearm.101,102 Recent studies also show GC-
induced reduction of IgE receptor-mediated expres-
sion  of  pro-inflammatory  cytokine  in  murine  bone
marrow derived mast cells.103
Inhibition of cytokine activity
It is clear that the expression and activity of several
important inflammatory cytokines may be suppressed
by prior treatment with glucocorticoids. Suppression
of cytokines expression, in general, appears not to be
due to interaction of the GC-R complex with GREs,
since  most  cytokine  genes  do  not  possess  a  GRE
element. The only clear exception to this is the IL-6
gene104,105 although there is some evidence for the
presence  of  a  GRE  on  the  IL-8  gene  of  a  human
fibrosarcoma cell line106 and more recently a negative
regulatory region containing a negative GRE has been
identified  in  the  human  IL-1b gene.107 Reports
suggest that the transcription of several cytokines is
lowered by the GCs following inactivation of specific
transcription  factors,  such  as  AP-1  and  NFk B,  as
described  earlier.  This  mode  of  action  has  been
suggested to be responsible for the attenuated pro-
duction  of  IL-6,  IL-8  and  IL-2.105,108,109 Finally  the
third mechanism for GC-induced inhibition of cyto-
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mRNA instability, i.e. a shortened half-life, for certain
cytokines (for e.g. see Lee et al.110). As mentioned the
GCs also inhibit the activity of many cytokines and
there is a vast literature documenting these actions
and  this  review  will  not  discuss  these  further.  Of
particular interest however have been the demonstra-
tions that the GC-sensitive actions of the cytokines in
models of cellular migration, specifically IL-1b and IL-
8,  are  mediated partially  by LC1.111 Additionally in
psoriatic  skin  both  IL-1  and  IL-6  are  significantly
elevated112,113 and  both  of  these  studies  postulate
that  these  cytokines  may  be  implicated  with  the
pathology of the disease.
Summary
The topical GCs still remain one of the most effective
and popular forms of treatment of various inflamma-
tory  skin  disease  states. These  agents  are  clearly  a
complex class of drugs that modulate the activity of
several pivotal processes and mediators of inflamma-
tion. Modulation of the levels and/or compartmentali-
zation  of  the  GC-inducible,  anti-inflammatory,  anti-
proliferative  protein,  LC1,  following  topical  GC
treatment  provides  solid  evidence  supporting  the
suggestion that this protein plays an important role in
the action of topical GCs. Exploration of the possibil-
ities of more specific treatment of skin disease with
LC1 related products may provide novel more efficient
modalities for treatment of inflammatory skin disease.
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